Effects of Alpha-Interferon on Serum Beta-2-Microglobulin

References

• Berggåd I., Bern A. G. Isolation and properties of a low molecular weight beetta-2-globulin occurring in human biological fluids. J. Biol. Chem 1968; 243: 4095–4103
   PubMed Web of Science ®Google Scholar
• Creswell P., Springer T., Strominger J. L., Turner M. J., Gray H. M., Kubo R. T. Immunological identity of the small subunit of HL-A antigens and β2-microglobulin and its turnover on the cell membrane. Proc. Natl. Acad. Sci. USA 1974; 71: 2123–2127
   PubMed Web of Science ®Google Scholar
• Peterson P. A., Rask L., östberg L. β2-Microglobulin and the major histocompatibility complex. Cancer Res 1977; 24: 115–163
   Google Scholar
• Cooper E. H., Plesner T. Beta-2-microglobulin review: its relevance in clinical oncology. Med. Pediatr. Oncol 1980; 8: 323–334
   PubMedGoogle Scholar
• Otten G. R., Bikoff E., Ribaudo R. K., Kozlowski S., Margulies D. H., Germain R. N. Peptide and β2-microglobulin regulation of cell surface MHC class I conformation and expression. J. Immunol 1992; 148: 3723–3732
   PubMed Web of Science ®Google Scholar
• Plesner T., Bjerrum O. J. Distribution of “free” and HLA-associated human β2-microglobulin in some plasma membranes and biological fluids. Scand. J. Immunol 1980; 11: 341–351
   PubMed Web of Science ®Google Scholar
• Wibell L. The serum level and urinary excretion of β2-microglobulin in health and renal disease. Pathol. Biol. (Paris) 1978; 26: 295–301
   PubMed Web of Science ®Google Scholar
• Bethea M., Forman D. T. β2-Microglobulin: its significance and clinical usefulness. Ann. Clin. Lab. Sci 1990; 20: 163–168
   PubMed Web of Science ®Google Scholar
• Viedma J. A., Pacheco S., Albaladejo M. D. Determination of β2-microglobulin in serum by a microparticle-enhanced nephelometric immunoassay. Clin. Chem 1992; 38: 2464–2468
   PubMed Web of Science ®Google Scholar
• Tienhaara A., Eskola J. U., Näntö V. Double monoclonal time-resolved immunofluorometric assay of β2-microglobulin in serum. Clin. Chem 1990; 36: 1961–1964
   PubMed Web of Science ®Google Scholar
• Evrin P. E., Wibell L. The serum levels and urinary excretion of β2-microglobulin in apparently healthy subjects. Scand. J. Clin. Lab. Invest 1972; 29: 69–74
   PubMed Web of Science ®Google Scholar
• Hemmingsen L., Skaarup P. β2-Microglobulin in urine and serum determined by ELISA technique. Scand. J. Clin. Lab. Invest 1985; 45: 367–371
   PubMed Web of Science ®Google Scholar
• Evrin P. E., Jansson N. O., Bergdahl A. A turbidimetric immunochemical method for determination of serum β2-microglobulin using a centrifugal analyzer. Clin. Chim. Acta 1986; 155: 151–158
   PubMed Web of Science ®Google Scholar
• Finn W., Huffman K., Forman D., Mandel S. Value of the serum β2-microglobulin/serum creatinine ratio following renal transplantation. Transplant. Proc 1984; 16: 1609–1612
   PubMed Web of Science ®Google Scholar
• Niederwieser D., Herold M., Woloszczuk W., Aulitzky W., Meister B., Tilg H., Gastl G., Bowden R., Huber C. Endogenous IFN-gamma during human bone marrow transplantation. Transplantation 1990; 50: 620–625
   PubMed Web of Science ®Google Scholar
• Wallach D., Fellous M., Revel M. Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 1982; 299: 833–836
   PubMed Web of Science ®Google Scholar
• Jones R. A., Drexler H. G., Gignac S. M., Child J. A., Scott C. S. In vitro beta2-microglobulin (β2m) secretion by normal and leukaemic B-cells: effects of recombinant cytokines and evidence for a differential response to the combined stimulus of phorbol ester and calcium ionophore. Br J Cancer 1990; 61: 675–680
   PubMed Web of Science ®Google Scholar
• Bataille R., Durie B. G. M., Grenier J. Serum beta2 microglobulin and survival in multiple myeloma: a simple and reliable marker for staging. Br. J. Haematol 1983; 55: 439–447
   PubMed Web of Science ®Google Scholar
• Scarffe J. H., Anderson H., Palmer M. K., Crowther D. Prognostic significance of pretreatment serum β2-microglobulin levels in multiple myeloma. Eur. J. Cancer Clin. Oncol 1983; 19: 1361–1364
   PubMedGoogle Scholar
• Garewal H., Durie B. G. M., Kyle R. A., Finley P., Bower B., Serokman R. Serum beta2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J. Clin. Oncol 1984; 2: 51–57
   PubMed Web of Science ®Google Scholar
• Melillo L., Musto P., Tomasi P., Cascavilla N., Bodenizza C., Ladogana S., Carotenuto M. Serum beta2-microglobulin in malignant lymphoproliferative disorders. Tumor 1988; 74: 129–135
   PubMed Web of Science ®Google Scholar
• Cuzick J., Cooper E. H., MacLennan I. C. M. The prognostic value of serum β2 microglobulin compared with other presentation features in myelomatosis. Br. J. Cancer 1985; 52: 1–6
   PubMed Web of Science ®Google Scholar
• Bataille R., Durie B. G. M., Grenier J., Sany J. Prognostic factors and staging in multiple myeloma: a reappraisal. J. Clin. Oncol 1986; 4: 80–87
   PubMed Web of Science ®Google Scholar
• Bataille R., Grenier J., Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment–a prospective study of 160 patients. Blood 1984; 63: 468–476
   PubMed Web of Science ®Google Scholar
• Durie B. G. M., Stock-Novack D., Salmon S. E., Finley P., Beckord J., Crowley J., Coltman C. A. Prognostic value of pretreatment serum β2 microglobulin in myeloma: a Southwest Oncology Group study. Blood 1990; 75: 823–830
   PubMed Web of Science ®Google Scholar
• Ellegaard J., Mogensen C. E., Kragballe K. Serum beta2-microglobulin in acute and chronic leukaemia. Scand. J. Haematol 1980; 25: 275–285
   PubMedGoogle Scholar
• Kantarjian H. M., Smith T., Estey E., Polyzos A., O'Brien S., Pierce S., Beran M., Feldman E., Keating M. J. Prognostic sifnificance of elevated serum β2-microglobulin levels in adult acute lymphocytic leukemia. Am. J. Med 1992; 93: 599–604
   PubMed Web of Science ®Google Scholar
• Litam P., Swan F., Cabanillas F., Tucker S. L., McLaughlin P., Hagemeister F. B., Rodriguez M. A., Velasquez W. S. Prognostic value of serum beta 2 microglobulin in low-grade lymphoma. Ann. Intern. Med 1991; 114: 855–860
   PubMed Web of Science ®Google Scholar
• Aviles A., Zepeda G., Diaz-Maqueo J. C., Rodriguez L., Guzman R., Garcia E. L., Talavera A. Beta 2 microglobulin level as an indicator of prognosis in diffuse large cell lymphoma. Leuk. Lymph 1992; 7: 135–138
   PubMed Web of Science ®Google Scholar
• Johnson P. W. M., Whelan J., Longhurst S., Stepniewska K., Matthews J., Amess J., Norton A., Rohatiner A. Z. S., Lister T. A. β-2 Microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br. J. Cancer 1993; 67: 792–797
   PubMed Web of Science ®Google Scholar
• Galvani D., Griffiths S. D., Cawley J. C. Interferon for treatment: the dust settles. Br. Med. J 1988; 296: 1554–1556
   PubMed Web of Science ®Google Scholar
• Baron S., Tyring S. K., Fleischmann W. R., Jr., Coppenhaver D. H., Niesel D. W., Klimpel G. R., Stanton G. J., Hughes T. K. The interferons. Mechanisms of action and clinical applications. J.A.M.A 1991; 266: 1375–1383
   PubMed Web of Science ®Google Scholar
• Mandelli F., Avvisati G., Amadori S., Boccadoro M., Gernone A., Lauta V. M., Marmont F., Petrucci M. T., Tribalto M., Vegna M. L., Dammacco F., Pileri A. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med 1990; 332: 1430–1434
   Web of Science ®Google Scholar
• Westin J., Rödjer S., Turesson I., Cortelezzi A., Hjorth M., Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br. J. Haematol 1995; 89: 561–568
   PubMed Web of Science ®Google Scholar
• Attal M., Huguet F., Schlaifer D., Payen C., Lassoued S., Laroche M., Rossi J.-F., Fournie B., Mazieres B., Pris J., Laurent G. Maintenance tratment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy. Bone Marrow Transplant 1991; 8: 125–128
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P., Lepage E., Brousse N., Reyes F., Haioun C., Leporrier M., Peuchmaur M., Bosly A., Parlier Y., Brice P., Coiffier B., Gisselbrecht C. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N. Engl. J. Med 1993; 329: 1608–1614
   PubMed Web of Science ®Google Scholar
• Horning S. J. Low-grade lymphoma 1993: state of the art. Ann. Oncol 1994; 5: 23–27, Suppl. 2
   PubMedGoogle Scholar
• Kurzrock R., Talpaz M., Gutterman J. U. Interferons–α, β, γ. basic principles and preclinical studies. Biologic Therapy of Cancer, V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg. J. B. Lippincott Company, Philadelphia 1991; 247–274
   Google Scholar
• Drews J. Immunopharmacology. Principles and perspectives. Roche Scientific Service, Basel 1990; 209–218
   Google Scholar
• Opat P., Drbal J., Tauer Z., Wotke R. Alteration of beta-2-microglobulin level in malignant lymphoproliferative diseases after a high dose of alpha-2-recombinant interferon. Eur. J. Cancer Clin. Oncol 1988; 24: 1295–1298
   PubMedGoogle Scholar
• Nachbaur K., Troppmair J., Kotlan B., König P., Aulitzky W., Bieling P., Huber C. Cytokines in the control of beta-2 microglobulin release. II. In vivo studies with recombinant interferons and antigens. Immunobiol 1988; 177: 66–75
   PubMed Web of Science ®Google Scholar
• Demeter J., Paloczi K., Bibok G., Lehoczky D. Differentiation and activation antigens on blood mononuclear cells in lymphocytic leukemia before and during IFN-alpha 2B therapy. Leukemia 1992; 6: 41–45, Suppl. 3
   PubMedGoogle Scholar
• Fuchs D., Norkrans G., Wejstal R., Reibnegger G., Weiss G., Weiland O., Schvarcz R., Fryden A., Wachter H. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b. Eur. J. Med 1992; 1: 196–200
   PubMedGoogle Scholar
• Wejstal R., Norkrans G., Weiland O., Schvarcz R., Fuchs D., Wachter H., Fryden A., Glaumann H. Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment. Clin. Exp. Immunol 1992; 87: 340–345
   PubMed Web of Science ®Google Scholar
• Hayata T., Nakano Y., Yoshizawa K., Sodeyarna T., Kiyosawa K. Effects of interferon on intrahepatic human leukocyte antigens and lymphocyte subsets in patients with chronic hepatitis B and C. Hepatology 1991; 13: 1022–1028
   PubMed Web of Science ®Google Scholar
• de Wit R., Bakker P. J., Reiss P., Hoek F. J., Lange J. M., Goudsmit J., Veenhof K. H. Temporary increase in serum beta 2-microglobulin during treatment with interferon-alpha for AIDS-associated Kaposi's sarcoma. AIDS 1990; 4: 459–462
   PubMed Web of Science ®Google Scholar
• Aulitzky W. E., Peschel C., Despres D., Aman J., Trautman P., Tilg H., Rudolf G., Huttmann H., Obermeier J., Herold M., Huber C. Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia. Ann. Hematol 1993; 67: 205–211
   PubMed Web of Science ®Google Scholar
• Liberati A. M., Schippa M., Portuesi M. G., Grazia-Proietti M., DeAngelis V., Ferrajoli A., Cinieri S., DiClemente F., Palmisano L., Berruto P. IFN-beta induced biochemical and immunological modifications in hairy cell leukemia patients. Haematologica 1991; 76: 375–382
   PubMedGoogle Scholar
• Aulitzky W. E., Grosse-Wilde H., Westhoff U., Tilg H., Aulitzky W., Gastl G., Herold M., Huber C. Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma. Clin. Exp. Immunol 1991; 86: 236–239
   PubMed Web of Science ®Google Scholar
• Schiller J. H., Storer B., Paulnock D. M., Brown R. R., Datta S. P., Witt P. L., Borden E. C. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J. Clin. Invest 1990; 86: 1211–1221
   PubMed Web of Science ®Google Scholar
• Schiller J. H., Hank J., Storer B., Borchert A. A., Moore K. H., Albertini M., Bechhofer R., Wesley O., Brown R. R., Bastin A. M., Sondel P. M. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans. Cancer Res 1993; 53: 1286–1292
   PubMed Web of Science ®Google Scholar
• Remes K., Tienhaara A., Pelliniemi T.-T. Priming therapy with alpha-interferon in chemotherapy-resistant multiple myeloma. Leuk. Lymph 1992; 6: 239–243
   Web of Science ®Google Scholar
• Tienhaara A., Remes K., Pelliniemi T.-T. Alpha interferon raises serum beta-2-microglobulin in patients with multiple myeloma. Br. J. Haematol 1991; 77: 335–338
   PubMed Web of Science ®Google Scholar
• Remes K., Tienhaara A., Pelliniemi T.-T. Alpha interferon raises serum beta-2-microglobulin in patients treated for thrombocythaemia. Br. J. Haematol 1993; 84: 353–355
   PubMed Web of Science ®Google Scholar
• Osterborg A., Björkholm M., Björeman M., Brenning G., Carlson K., Celsing F., Gahrton G., Grimfors G., Gyllenhammer G., Hast R., Johansson B., Juliusson G., Järnark M., Kimby E., Lemer R., Linder O., Merk K., Nilsson B., Ohrling M., Paul C., Simonsson B., Smedmyr B., Stalfelt A.-M., Strander H., Uden A., Ösby E., Mellstedt H. Natural interferon-alfa in combination with melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993; 81: 1428–1434
   PubMed Web of Science ®Google Scholar
• Tanaka H., Tanabe O., Iwato K., Asaoku H., Ishikawa H., Nobuyoshi M., Kawano M., Kuramoto A. Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells. Blood 1989; 74: 1718–1722
   PubMed Web of Science ®Google Scholar
• Hofmann B., Bass H., Nishanian P., Faisal M., Figlin R. A., Sama G. P., Fahey J. L. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha. Clin. Exp. Immunol 1992; 88: 548–554
   PubMed Web of Science ®Google Scholar